Research overview
What is GHK-Cu + BPC-157 (Glow Blend)?
This catalog label refers to two different peptides in one proposed mixture: GHK-Cu, a copper-binding tripeptide complex, and BPC-157, a synthetic pentadecapeptide. “Glow Blend” is not a standardized clinical drug name. Amounts, chemical forms, copper content, and even the presence of both ingredients cannot be inferred from the shorthand.
What has research examined?
GHK-Cu has been examined in cultured fibroblast collagen assays and animal wound models. BPC-157 has been studied mainly in rodent tendon/ligament injury models. Those separate tests used different materials and endpoints; they do not test a fixed GHK-Cu/BPC-157 blend or establish an additive effect. FDA has raised safety and impurity-characterization concerns relevant to proposed compounded injectable forms of each constituent.
No direct controlled evidence cited here validates the mixture, its ratio, route, safety, or benefit. Separate component papers must not be presented as blend results. This page does not advise preparation or use.
Research references
- GHK-Cu stimulation of collagen synthesis in fibroblast cultures (component only)Journal of Biological Chemistry; GHK-Cu component
- BPC-157 in a transected rat Achilles tendon model (component only)Journal of Orthopaedic Research; BPC-157 component
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration
Calculation boundary
A blend’s total vial mass cannot specify the amount of each ingredient without an exact, independently verified component breakdown. A generic single-compound syringe chart could falsely imply equal or known concentrations for GHK-Cu and BPC-157.